Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wheaton Precious Metals Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Wheaton Precious Metals Corp trades at $109.68 (market cap $49.85B). The key difference: Wheaton Precious Metals Corp is the larger of the two by market cap, and Wheaton Precious Metals Corp pays a 0.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WPM | |
|---|---|---|
Market Cap | $39.89B | $49.85B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $165.72 |
52-Week Low | $278.09 | $88.32 |
Enterprise Value | $38.15B | $47.69B |
Dividend Yield | — | 0.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Wheaton Precious Metals (WPM) trades at $110.05, down 0.54% on the day, amid a bearish technical signal. The company exhibits strong fundamentals with 2025 revenue of $2.31B, net income of $1.47B, and consistent earnings beats. Analyst consensus is strongly bullish with a $163 price target, though recent news highlights sensitivity to precious metal price volatility.
WPM offers a compelling growth story with robust profitability and positive cash flow, but faces risks from commodity price swings and acquisition integration. The stock's current discount to analyst targets presents a potential opportunity for long-term investors, contingent on stable metal prices and execution of production outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
